drugset / Trial / NCT04090775
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study seeks to estimate the occurrence of adverse events related to the study treatment (Cryosurgical freezing and Intratumoral Combination Immunotherapy), as well as determine the potential efficacy.
Timeline
- Start
- 2019-06-28
- Primary completion
- 2020-07-30
- Completion
- 2022-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 25 mg | Other |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | Other |
| Subject | Cyclophosphamide | Other / unclassified | 250 mg/m2 | Other |
| Subject | Ipilimumab | Monoclonal antibody | 5 mg | Other |
| Subject | Nivolumab | Monoclonal antibody | 10 mg | Other |